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Albumin-like material in urine. Recent studies have demon-
strated the presence, in both rat and human urine, of a modified
form of albumin not detected by conventional antibodies. This
modified albumin behaves physicochemically as intact albumin
under nondenaturing conditions. We have demonstrated this
form of albumin to be disproportionately excreted in microal-
buminuric states in diabetes. Quantitation of this modified form
of albumin leads to the prediction of the onset of microalbumin-
uria in diabetic patients on average 3 to 4 years earlier than when
measured by conventional immunoassays.
Recent studies have demonstrated that diabetic
patients produce urine that contains relatively large
quantities of an intact modified form of albumin that
is undetected by conventional albumin antibodies. Im-
munounreactive albumin behaves physicochemically in
terms of size, shape, and charge like native albumin. This
study examines in more detail the nature of this intact
modified form of albumin.
METHODS
Intact modified form of albumin, found at relatively
high levels in the urine of diabetic patients, has been
examined by HPLC, native polyacrylamide gel elec-
trophoresis (PAGE), immunoassays, and capillary elec-
trophoresis. The modified form of albumin, isolated from
urine using affinity chromatography, has also been ana-
lyzed.
RESULTS AND DISCUSSION
Figure 1 shows native PAGE profiles of urine col-
lected from diabetic patients over 24 hours. This study
demonstrates that the major band in the urine comigrates
with the albumin standard. The bands have been con-
firmed as albumin by liquid chromatography coupled to
an MS/MS instrument (Q-TOF) (performed by the Aus-
tralian Proteome Analysis Facility, Sydney, Australia).
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The concentrations of albumin in each of these samples
was determined by high performance liquid chromatog-
raphy (HPLC, which measures total intact albumin =
immunoreactive + immunounreactive). Immunoreactive
albumin was determined by radioimmunoassay (RIA).
The study clearly indicates that for samples where the
immunoassay would measure low or negligible levels of
albumin, considerable albumin is present as seen by gel
staining and HPLC. A good linear correlation was found
between quantitation of the amount of material in the
band by densitometric analysis and HPLC, but not RIA.
Figure 2 demonstrates that other plasma proteins run
quite differently to albumin on native PAGE. Tamm-
Horsfall glycoprotein was not detected in diabetic urine,
as determined by capillary electrophoresis. Purified mod-
ified albumin preparations have also been shown to have
nondetectable quantities of these plasma proteins, as
well as Na+/K+-ATPase beta subunit, as determined by
enzyme-liked immunosorbent assay (ELISA).
Various experiments to test the stability of immunoun-
reactive albumin have demonstrated that it is stable at
both −20◦C and −70◦C for up to a month, and is also
stable for at least six freeze-thaw cycles.
The potential usefulness of detecting immunounreac-
tive albumin has been demonstrated recently in a ret-
rospective study [1]. The retrospective study examined
the differential lead-time for the development of mi-
croalbuminuria as measured by both conventional RIA
(measures immunoreactive) and HPLC (measures total
albumin = immunoreactive plus immunounreactive). For
type 1 progressors, the mean lead-time for the HPLC as-
say versus the RIA was 3.9 years, with a 95% confidence
interval of 2.1 to 5.6 years. For type 2 progressors, the
mean lead-time was 2.4 years with a 95% confidence in-
terval of 1.2 to 3.5 years. There was no significant differ-
ence between the lead-time analysis between type 1 and
type 2 diabetic patients. For the type 1 nonprogressors
there was no significant difference (P = 0.056) between
the false positives for the HPLC assay (6/280 urines, 2.1%,
CI of 0.8–4.6) and RIA (1/280 urines, 0.4%, CI of 0–2.0).
For the type 2 nonprogressors, the false positives for the
HPLC assay (28/265 urines, 10.6%, CI of 7.1–14.9) were
significantly higher (P < 0.0005) than those for the RIA
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Fig. 1. Native PAGE analysis of diabetic urines from different indi-
vidual patients containing various amounts of immunoreactive intact
albumin and immunounreactive intact albumin. The amount of albu-
min determined by HPLC and RIA are shown, as well as the position
of the albumin monomer.
(0/265 urines, 0%, CI of 0–1.4). For the type 1 progressors
the false negatives for the RIA (67/121 urines, 55.4%, CI
of 46.1–64.4) were significantly higher (P < 0.0005) than
those for the HPLC (0/121 urines, 0%, CI of 0–3.0). Sim-
ilarly, for the type 2 progressors the false negatives for
the RIA (78/190 urines, 41.1%, CI of 33.9–48.4) were sig-
nificantly higher (P < 0.0005) than those for the HPLC
(5/190 urines, 2.6%, CI of 33.9–48.4).
CONCLUSION
These results demonstrate that measurement of total
albumin including immunounreactive albumin may allow
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Fig. 2. Native PAGE of albumin compared to position of other plasma
protein standards. Albumin runs differently to a1-antitrypsin, transfer-
rin, a1-acid glycoprotein, a2-HS-glycoprotein. IgG did not enter the
gel.
earlier detection of microalbuminuria associated with di-
abetic nephropathy.
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